Last reviewed · How we verify
Goprelto (COCAINE)
At a glance
| Generic name | COCAINE |
|---|---|
| Sponsor | Lxo Ireland |
| Drug class | cocaine |
| Target | Sodium-dependent dopamine transporter |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 2017 |
Approved indications
- Local anesthesia
Boxed warnings
- WARNING: ABUSE AND DEPENDENCE CNS stimulants, including cocaine hydrochloride, have a high potential for abuse and dependence [see Warning and Precautions (5.1) . ] WARNING: ABUSE AND DEPENDENCE See full prescribing information for complete boxed warning. CNS stimulants, including cocaine hydrochloride, have a high potential for abuse and dependence. (5.1)
Common side effects
- Headache
- Epistaxis
- Anxiety
Drug interactions
- CYP2D6 Substrates
- Ioflupane I-123
Key clinical trials
- AAV8-hCocH for Cocaine Use Disorder (PHASE1)
- Impact of Different Fasting Strategies on Gastric Ultrasound and Anxiety Levels in Children (NA)
- (Effect of Toy Nebulizer Versus Distraction Cards on Children's Fear and Parental Satisfaction During Nebulization Therapy: A Comparative Study (NA)
- Harm Reduction Services (NA)
- Repurposing Semaglutide for the Treatment of Cocaine Use Disorder (PHASE2)
- Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder (PHASE2)
- Cola Ingestion for Esophageal Bolus Impaction (NA)
- Exenatide For Reducing the Reinforcing Effects of Cocaine (PHASE1)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |